Glioblastoma therapy: going beyond Hercules Columns

References

• Furnari FB, Fenton T, Bachoo RM et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev.21, 2683–2710 (2007).
   PubMed Web of Science ®Google Scholar
• Parsons DW, Jones S, Zhang X et al. An integrated genomic analysis of human glioblastoma multiforme. Science321(5897), 1807–1812 (2008).
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature455(7216), 1061–1068 (2008).
   PubMed Web of Science ®Google Scholar
• Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery62(4), 753–764 (2008).
   PubMed Web of Science ®Google Scholar
• Simpson JR, Horton J, Scott C et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int. J. Radiat. Oncol. Biol. Phys.26, 239–244 (1993).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Tosoni A, Franceschi E et al. Glioblastoma in adults. Crit. Rev. Oncol. Hematol.67(2), 139–152 (2008).
   PubMed Web of Science ®Google Scholar
• Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N. Engl. J. Med.356, 1527–1535 (2007).
   PubMed Web of Science ®Google Scholar
• Ford JM, Seiferheld W, Alger JR et al. Results of the Phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys.69, 831–838 (2007).
   PubMedGoogle Scholar
• Hegi ME, Diserens AC, Gorlia T et al.MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med.352, 997–1003 (2005).
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol.10(5), 459–466 (2009).
   PubMed Web of Science ®Google Scholar
• Lefranc F, Facchini V, Kiss R. Pro-autophagic drugs: a novel means to combat apoptosis-resistant cancers. Oncologist12, 1395–1403 (2007).
   PubMed Web of Science ®Google Scholar
• Mathieu V, De Nève N, Le Mercier M et al. Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia10(12), 1383–1392 (2008).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Tosoni A, Basso U et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a Phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J. Clin. Oncol.22, 4779–4786 (2004).
   PubMed Web of Science ®Google Scholar
• Franceschi E, Omuro AM, Lassman AB, Demopoulos A, Nolan C, Abrey LE. Salvage temozolomide for prior temozolomide responders. Cancer104, 2473–2476 (2005).
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK, Wang MY, Vivanco I et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med.353, 2012–2024 (2005).
   PubMed Web of Science ®Google Scholar
• Haas-Kogan DA, Prados MD, Tihan T et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl Cancer Inst.97, 880–887 (2005).
   PubMed Web of Science ®Google Scholar
• Lassman AB, Rossi MR, Razier JR et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium trials 01–03 and 00–01. Clin. Cancer Res.11, 7841–7850 (2005).
   PubMed Web of Science ®Google Scholar
• Rich JN, Reardon DA, Peery T et al. Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol.22(1), 133–142 (2004).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Brandes AA, Rampling R et al. Randomized Phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J. Clin. Oncol.27(8), 1268–1274 (2009).
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE II et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol.25, 4722–4729 (2007).
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell11, 83–95 (2007).
   PubMed Web of Science ®Google Scholar
• Chang SM, Wen P, Cloughesy T et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest. New Drugs23, 357–361 (2005).
   PubMed Web of Science ®Google Scholar
• Galanis E, Buckner JC, Maurer MJ et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol.23(23), 5294–5304 (2005).
   PubMed Web of Science ®Google Scholar
• Guha A, Dashner K, Black PM, Wagner JA, Stiles CD. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int. J. Cancer60, 168–173 (1995).
   PubMed Web of Science ®Google Scholar
• George D. Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Semin. Oncol.28(Suppl. 17), 27–33 (2001).
   PubMed Web of Science ®Google Scholar
• Raymond E, Brandes A, Van Osterom A et al. Multicenter Phase II study of imatinib mesylate in patients with recurrent glioblastoma: an EORTC NCCG/BTG Intergroup study. 2004 ASCO Annual Meeting Proceedings. J. Clin. Oncol.22(14S), 1501 (2004).
   PubMedGoogle Scholar
• van den Bent M, Brandes A, Frenay M et al. Multicenter Phase II study of imatinib mesylate in patients with recurrent anaplastic oligodendroglioma (AOD)/mixed oligoastrocytoma (MOA) and anaplastic astrocytoma (AA)/low-grade astrocytoma (LGA): an EORTC New Drug Development Group (NDDG) and Brain Tumor Group (BTG) study. 2005 ASCO Annual Meeting Proceedings. J. Clin. Oncol.23(16S), 1517 (2005).
   Google Scholar
• Raymond E, Campone M, Stupp R et al. Multicenter Phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme. Eur. J. Cancer38, 1348–1350 (2002).
   PubMed Web of Science ®Google Scholar
• Dresemann G. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann. Oncol.16, 1702–1708 (2005).
   PubMed Web of Science ®Google Scholar
• Westphal M, Hilt DC, Bortey E et al. A Phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol.5, 79–88 (2003).
   PubMed Web of Science ®Google Scholar
• Olivi A, Grossman SA, Tatter S et al. Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial. J. Clin. Oncol.21(9), 1845–1849 (2003).
   PubMed Web of Science ®Google Scholar
• Galli R, Binda E, Orfanelli U et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res.64, 7011–7021 (2004).
   PubMed Web of Science ®Google Scholar
• Singh SK, Clarke ID, Hide T, Dirks PB. Cancer stem cells in nervous system tumors. Oncogene23, 7267–7273 (2004).
   PubMed Web of Science ®Google Scholar
• Salmaggi A, Boiardi A, Gelati M et al. Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia54(8), 850–860 (2006).
   PubMed Web of Science ®Google Scholar
• Ishikawa E, Tsuboi K, Saijo K et al. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res.24, 1861–1871 (2004).
   PubMed Web of Science ®Google Scholar
• Yajima N, Yamanaka R, Mine T et al. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin. Cancer Res.11, 5900–5911 (2005).
   PubMed Web of Science ®Google Scholar
• Caruso DA, Orme LM, Neale AM et al. Results of a Phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro Oncol.6, 236–246 (2004).
   PubMed Web of Science ®Google Scholar
• Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T cells in patients with malignant glioma. Cancer Res.64, 4973–4979 (2004).
   PubMed Web of Science ®Google Scholar
• Rutkowski S, De Vleeschouwer S, Kaempgen E et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma: a feasibility study. Br. J. Cancer91, 1656–1662 (2004).
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Homma J, Yajima N et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical Phase I/II trial. Clin. Cancer Res.11(11), 4160–4167 (2005).
   PubMed Web of Science ®Google Scholar
• Badie B, Schartner J, Prabakaran S, Paul J, Vorpahl J. Expression of fas ligand by microglia: possible role in glioma immune evasion. J. Neuroimmunol.120, 19–24 (2001).
   PubMed Web of Science ®Google Scholar
• Morandi E, Zingaretti C, Chiozzotto D et al. A cDNA-microarray analysis of camptothecin resistance in glioblastoma cell lines. Cancer Lett.231, 74–86 (2006).
   PubMed Web of Science ®Google Scholar
• Yu JS, Luptrawan A, Black KL, Liu G. Mahaley clinical research award: chemosensitization of glioma through dendritic cell vaccination. Clin. Neurosurg.53, 345–351 (2006).
   Google Scholar
• Liu G, Akasaki Y, Khong HT et al. Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy. Oncogene24, 5226–5234 (2005).
   PubMed Web of Science ®Google Scholar
• Parney IF, Chang LJ, Farr-Jones MA, Hao C, Smylie M, Petruk KC. Technical hurdles in a pilot clinical trial of combined B7–2 and GM-CSF immunogene therapy for glioblastomas and melanomas. J. Neurooncol.78, 71–80 (2006).
   PubMed Web of Science ®Google Scholar
• Steiner HH, Bonsanto MM, Beckhove P et al. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J. Clin. Oncol.22(21), 4272–4281 (2004).
   PubMed Web of Science ®Google Scholar
• Burger PC, Dubois PJ, Schold SC Jr et al. Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J. Neurosurg.58, 159–169 (1983).
   PubMed Web of Science ®Google Scholar
• Silbergeld DL, Chicoine MR. Isolation and characterization of human malignant glioma cells from histologically normal brain. J. Neurosurg.86, 525–531 (1997).
   PubMed Web of Science ®Google Scholar
• Schiffer D, Cavalla P, Dutto A, Borsotti L. Cell proliferation and invasion in malignant glioma. Anticancer Res.17, 61–69 (1997).
   Google Scholar
• Dalrymple SJ, Parisi JE, Roche PC, Ziesmer SC, Scheithauer BW, Kelly PJ. Changes in proliferating cell nuclear antigen expression in glioblastoma multiforme cells along a stereotactic biopsy trajectory. Neurosurgery35, 1036–1044 (1994).
   Google Scholar
• Berens ME, Giese A. ‘‘…those left behind.’’ Biology and oncology of invasive glioma cells. Neoplasia1, 208–219 (1999).
   PubMedGoogle Scholar
• Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J. Clin. Oncol.23(10), 2411–2422 (2005).
   PubMed Web of Science ®Google Scholar
• Mangiola A, de Bonis P, Maira G et al. Invasive tumor cells and prognosis in a selected population of patients with glioblastoma multiforme. Cancer113(4), 841–846 (2008).
   PubMed Web of Science ®Google Scholar
• Lama G, Mangiola A, Anile C et al. Activated ERK1/2 expression in glioblastoma multiforme and in peritumor tissue. Int. J. Oncol.30(6), 1333–1342 (2007).
   Google Scholar
• Mangiola A, Lama G, Giannitelli C et al. Stem cell marker nestin and c-Jun NH2-terminal kinases in tumor and peritumor areas of glioblastoma multiforme: possible prognostic implications. Clin. Cancer Res.13(23), 6970–6977 (2007). Erratum in: Clin. Cancer Res.14(15), 4995–4996 (2008).
   Google Scholar
• Piccirillo SG, Combi R, Cajola L et al. Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution. Oncogene28(15), 1807–1811 (2009).
   PubMedGoogle Scholar
• le Sage C, Nagel R, Egan DA et al. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J.26(15), 3699–3708 (2007).
   PubMed Web of Science ®Google Scholar
• Ciafre SA, Galardi S, Mangiola A et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem. Biophys. Res. Commun.334, 1351–1358 (2005).
   PubMed Web of Science ®Google Scholar